Cargando…

Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial

BACKGROUND: In a randomized phase II trial conducted in patients with metastatic melanoma, patient-specific autologous dendritic cell vaccines (DCV) were associated with longer survival than autologous tumor cell vaccines (TCV). Both vaccines presented antigens from cell-renewing autologous tumor ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nistor, Gabriel I., Dillman, Robert O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171762/ https://www.ncbi.nlm.nih.gov/pubmed/32316978 http://dx.doi.org/10.1186/s12967-020-02328-6

Ejemplares similares

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
por: Dillman, Robert O., et al.
Publicado: (2023)

Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
por: Dillman, Robert O., et al.
Publicado: (2018)

Phase III randomized, double-blinded, placebo-controlled multicenter trial of melapuldencil-t: autologous dendritic cells loaded with irradiated autologous tumor cells (dc-tc) in gm-csf in patients with metastatic melanoma
por: Dillman, Robert, et al.
Publicado: (2014)

Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B positive patients with hepatocellular carcinoma
por: Bayer, Michael, et al.
Publicado: (2014)

Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B‐positive patients with hepatocellular carcinoma
por: Wang, Xiaojin, et al.
Publicado: (2015)

Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
por: Dillman, Robert O, et al.
Publicado: (2019)

Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine
por: Dillman, Robert O., et al.
Publicado: (2019)

Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines
por: Dillman, Robert O, et al.
Publicado: (2015)

Influence of Immunotherapy with Autologous Dendritic Cells on Innate and Adaptive Immune Response in Cancer
por: Matias, Bruna F., et al.
Publicado: (2013)

Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy with Cytokine-Induced Killer Cells Improves Survival in Gastric and Colorectal Cancer Patients
por: Gao, Daiqing, et al.
Publicado: (2014)

Autologous Peripheral Blood Mononuclear Cell Recognition of Autologous Proliferating Tumor Cells in the Context of a Patient-Specific Vaccine Trial
por: Cornforth, A. N., et al.
Publicado: (2011)

Optimizing tumor-associated antigen-stimulated autologous dendritic cell and cytokine-induced killer cell coculture to enhance cytotoxicity for cancer immunotherapy in manufacturing
por: Lee, Yi-Yen, et al.
Publicado: (2023)

Immunotherapy of Malignant Melanoma with Tumor Lysate-Pulsed Autologous Monocyte-Derived Dendritic Cells
por: Kim, Dae Suk, et al.
Publicado: (2011)

Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment
por: Dillman, Robert O., et al.
Publicado: (2015)

Preliminary observations on soluble programmed cell death protein-1 as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines
por: Dillman, Robert O., et al.
Publicado: (2019)

Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines
por: de Gruijl, Tanja D., et al.
Publicado: (2008)

The Role of T Lymphocytes in Cancer Patients Undergoing Immunotherapy with Autologous Dendritic Cells
por: Rodrigues, Cláudia M., et al.
Publicado: (2011)

Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment
por: Dillman, Robert Owen, et al.
Publicado: (2019)

Manipulation of the tumor microenvironment by cytokine gene transfection enhances dendritic cell‐based immunotherapy
por: Wijesekera, Daluthgamage Patsy Himali, et al.
Publicado: (2019)

Immune Regulation by Dendritic Cell Extracellular Vesicles in Cancer Immunotherapy and Vaccines
por: Fernández-Delgado, Irene, et al.
Publicado: (2020)

FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy
por: Fiammenghi, Laura, et al.
Publicado: (2010)

Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma
por: Parney, Ian F, et al.
Publicado: (2020)

Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors
por: Kalkusova, Katerina, et al.
Publicado: (2022)

Autologous tumor lysate-loaded dendritic cell vaccination combined with Sunitinib for metastatic renal cell carcinoma
por: Kakimi, Kazuhiro, et al.
Publicado: (2014)

Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea
por: Kong, Doo-Sik, et al.
Publicado: (2016)

One Single Site Clinical Study: To Evaluate the Safety and Efficacy of Immunotherapy With Autologous Dendritic Cells, Cytokine-Induced Killer Cells in Primary Hepatocellular Carcinoma Patients
por: Xu, Kaiyue, et al.
Publicado: (2020)

Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA
por: Moreira, Alvaro, et al.
Publicado: (2020)

Dendritic Cell-Based Immunotherapy for Solid Tumors()()
por: Jung, Nam-Chul, et al.
Publicado: (2018)

Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy
por: Peng, Xin, et al.
Publicado: (2021)

High-dose IL-2 in metastatic melanoma: better survival in patients who also received patient-specific autologous tumor cell vaccine
por: Dillman, Robert O, et al.
Publicado: (2013)

Engineering dendritic cell vaccines to improve cancer immunotherapy
por: Perez, Caleb R., et al.
Publicado: (2019)

Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy
por: Pan, Hong, et al.
Publicado: (2021)

Research progress on dendritic cell vaccines in cancer immunotherapy
por: Yu, Jifeng, et al.
Publicado: (2022)

Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients
por: Shinde, Prajakta, et al.
Publicado: (2019)

Rapid Isolation of Gastric Adenocarcinoma Cancer Stem Cells as a Target for Autologous Dendritic Cell-Based Immunotherapy
por: Bagheri, Vahid, et al.
Publicado: (2022)

Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
por: Bota, Daniela A., et al.
Publicado: (2022)

Cytokine-induced killer cell/dendritic cell combined with cytokine-induced killer cell immunotherapy for treating advanced gastrointestinal cancer
por: Du, Hansong, et al.
Publicado: (2020)

Human Immune System Mice With Autologous Tumor for Modeling Cancer Immunotherapies
por: Sun, Liguang, et al.
Publicado: (2020)

Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells
por: Calmeiro, João, et al.
Publicado: (2020)

Dendritic cell biology and its role in tumor immunotherapy
por: Wang, Yingying, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vj9clits3bmfmglnqkk8j55ml7